KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
MWN-AI** Summary
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has announced that five abstracts, including a late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership Conference in Madrid, Spain, scheduled from March 26-29, 2026. These presentations are particularly noteworthy as they include interim data from the KONFIDENT-KID trial, which evaluates their groundbreaking oral treatment, EKTERLY® (sebetralstat), in treating hereditary angioedema (HAE) attacks in children aged 2 to 11.
The featured late-breaking abstract, titled "On-demand Oral Sebetralstat for Hereditary Angioedema Attacks in Children Aged 2-11: Interim Analysis of KONFIDENT-KID," will be presented on March 28 at 11:50 AM CET. This trial is critical as it aims to establish the safety and efficacy of EKTERLY in a younger population who suffer from this rare genetic condition.
Additional poster presentations will address various dimensions of sebetralstat’s impact and treatment efficacy among individuals transitioning from injectable HAE treatments, patterns of on-demand treatment, and barriers faced by patients using subcutaneous therapies. Insights gathered from international surveys will also shed light on patient satisfaction and anxiety related to treatment protocols.
EKTERLY is currently recognized as the first and only oral on-demand therapy for HAE and is already approved in several regions for patients aged 12 and older. A US regulatory filing is expected in 2026 to expand its use to younger children, marking a significant step forward in HAE management. KalVista's commitment to developing transformational therapies for rare diseases underscores its position at the forefront of innovation in the field. For more details on these presentations, visit KalVista's official website.
MWN-AI** Analysis
KalVista Pharmaceuticals (Nasdaq: KALV) is on the cusp of significant advancements in managing hereditary angioedema (HAE) with its groundbreaking oral treatment, EKTERLY® (sebetralstat). The upcoming 2026 Global Angioedema Leadership Conference in Madrid, particularly the late-breaking presentation of interim data from the KONFIDENT-KID trial, promises to spotlight EKTERLY's potential to revolutionize care for children aged 2-11 suffering from this rare disease.
Investors should keep a close eye on the results from these presentations. Positive findings during the conference could bolster KalVista's stock price as they would validate the efficacy and safety of sebetralstat in a demographic currently underserved by available treatments. Notably, EKTERLY is already approved for patients aged 12 and older, making the upcoming trial outcomes pivotal for expanding its market reach.
With a planned regulatory filing in 2026 to extend use of sebetralstat to younger patients, coupled with previous data indicating high satisfaction rates among those switching from injectable therapies, KalVista is in a robust position to capture a larger market share. The oral nature of EKTERLY addresses common patient anxieties associated with injectables, a compelling selling point that could further differentiate it in the competitive landscape of HAE therapies, which primarily comprise parenteral options.
Moreover, the broader context of unmet medical needs within the HAE patient community amplifies the growth opportunity for KalVista. As global awareness and diagnosis of HAE rise, so too will the demand for effective, user-friendly treatments.
In summary, KalVista Pharmaceuticals appears poised for potential upside, making it a stock to watch in the coming months. Positive clinical results and regulatory progress can significantly impact investor sentiment and share price, suggesting a strong case for investment consideration.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation
KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership Conference taking place in Madrid, Spain from March 26–29, 2026.
The following late-breaking abstract will be presented during the poster session on Friday, March 27 and as an oral presentation on Saturday, March 28 at 11:50 am CET:
- On-demand Oral Sebetralstat for Hereditary Angioedema Attacks in Children Aged 2-11: Interim Analysis of KONFIDENT-KID: Emel Aygören-Pürsün , Adil Adatia, John Anderson, Shira Benor, Mélisande Bourgoin-Heck, Mauro Cancian, Bob Geng, Eisuke Inage, Aharon Kessel, Majed Koleilat, H. Henry Li, Michael E. Manning, Heloise Reumaux, Raffi Tachdjian, Paola Triggianese, Andrea Zanichelli, Erik Hansen, Ya-Hsiu Chuang, Matthew Iverson, Michael D. Smith, Paul K. Audhya, H. James Wedner.
The following poster presentations will take place during the poster session on Friday, March 27, beginning at 6:10 pm CET:
- Satisfaction with Sebetralstat for HAE Attacks in Patients Switching from Parenteral On-demand Treatments in KONFIDENT-S: Mauro Cancian , Laurence Bouillet, Teresa Caballero, Tariq El-Shanawany, Sorena Kiani-Alikhan, Markus Magerl, Michael E. Manning, Inmaculada Martinez-Saguer, Maeve E. O’Connor, Sinisa Savic, Daniel F. Soteres, Maria Staevska, James Hao, Paolo Bajcic, Paul Audhya, Raffi Tachdjian.
- On-demand Treatment Patterns of Hereditary Angioedema Attacks with Sebetralstat in the KONFIDENT-S Study: Mar Guilarte , Emel Aygören-Pürsün, Jonathan A. Bernstein, Danny M. Cohn, Vesna Grivcheva-Panovska, Tamar Kinaciyan, Damia Leguevaques, William R. Lumry, Michael E. Manning, Daniel F. Soteres, Petra Staubach, Raffi Tachdjian, Marcin Stobiecki, Marc A. Riedl, Anna Valerieva, Patrick F. K. Yong, Andrea Zanichelli, James Hao, Michael D. Smith, Paul K. Audhya, Henriette Farkas.
- Barriers to Treatment of Hereditary Angioedema Attacks Among Patients Using Subcutaneous On-Demand Therapies: Insights from an International Patient Survey: Thomas Buttgereit , Isabelle Boccon-Gibod, Alexis Bocquet, Laurence Bouillet, Paula Busse, Sandra Christiansen, Timothy Craig, Tariq El-Shanawany, Tomaz Garcez, Padmalal Gurugama, Rashmi Jain, Sorena Kiani-Alikhan, Markus Magerl, Inmaculada Martinez-Saguer, Maeve O’Connor, Cristine Radojicic, Sinisa Savic, Paola Triggianese, H. James Wedner, Patrick Yong, Andrea Zanichelli, Sherry Danese, Julie Ulloa, Paolo Bajcic, Paul K. Audhya, Mauro Cancian.
- Anxiety in Patients Using Injectable On-Demand Treatments for Hereditary Angioedema Attacks: Results from an International Patient Survey: Alexis Bocquet , Isabelle Boccon-Gibod, Laurence Bouillet, Paula Busse, Thomas Buttgereit, Sandra Christiansen, Timothy Craig, Tariq El-Shanawany, Tomaz Garcez, Padmalal Gurugama, Rashmi Jain, Sorena Kiani-Alikhan, Markus Magerl, Inmaculada Martinez-Saguer, Maeve O’Connor, Cristine Radojicic, Sinisa Savic, Paola Triggianese, H. James Wedner, Patrick Yong, Andrea Zanichelli, Sherry Danese, Julie Ulloa, Paolo Bajcic, Paul K. Audhya, Mauro Cancian.
Links to all presentations will be available on the KalVista website under Publications .
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity.
About EKTERLY® (sebetralstat)
EKTERLY (sebetralstat) is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland, Australia, Singapore and Japan for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. EKTERLY is the first and only oral on-demand treatment for HAE, offering efficacious and safe treatment of attacks without the burden of injections. With a US regulatory filing planned for 2026 to expand use to children aged 2–11, and additional filings anticipated in key global markets, EKTERLY has the potential to become the foundational therapy for HAE management worldwide. For more information, including the full US Prescribing Information , visit EKTERLY.com .
About KalVista Pharmaceuticals, Inc.
KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn , X , Facebook and Instagram .
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "position," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, information relating to our business and business plans, the success of our efforts to commercialize EKTERLY® (sebetralstat), our ability to successfully obtain foreign regulatory approvals for sebetralstat, our expectations about the safety and efficacy of sebetralstat, the timing of clinical trials and their results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and the ability of EKTERLY to treat HAE. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2025, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260320091603/en/
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Molly Cameron
Senior Director, Corporate Affairs
(978) 339-3378
molly.cameron@kalvista.com
FAQ**
How do the interim results from the KONFIDENT-KID trial for sebetralstat in children aged 2-impact the investment potential of KalVista Pharmaceuticals Inc. (KALV) in the context of its market position in hereditary angioedema treatments?
With the planned US regulatory filing in 20for children aged 2-11, what are analysts predicting regarding the potential revenue growth for KalVista Pharmaceuticals Inc. (KALV) from EKTERLY® in the pediatric segment of hereditary angioedema treatments?
Considering the late-breaking abstract presentation at the Global Angioedema Leadership Conference, how could the reception of this data influence investor sentiment towards KalVista Pharmaceuticals Inc. (KALV) in the broader pharmaceutical market?
How might the findings from the KONFIDENT-KID trial and patient surveys presented at the conference strengthen the case for KalVista Pharmaceuticals Inc. (KALV) as a leader in innovative therapies for hereditary angioedema?
**MWN-AI FAQ is based on asking OpenAI questions about KalVista Pharmaceuticals Inc. (NASDAQ: KALV).
NASDAQ: KALV
KALV Trading
2.88% G/L:
$19.135 Last:
870,583 Volume:
$19.14 Open:
